BioCentury | Nov 10, 2017
Product R&D

Blueprint gets the GIST

...et al. “Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. ” Nature (2010) Michael Leviten, Senior Writer BLU-285 Blueprint Bio Oregon...
BioCentury | Jul 1, 2016
Company News

Management tracks

...and neuroscience area head of global clinical development at Shire plc (LSE:SHP; NASDAQ:SHPG). Biomarkers company Blueprint Bio Inc....
BioCentury | Jun 27, 2016
Financial News

Blueprint Bio completes venture financing

Blueprint Bio Inc. , Newport Beach, Calif. Business: Diagnostic Date completed: 2016-06-23 Type: Venture financing Raised: $7.5 million Investor: Forentis Fund WIR Staff Diagnostic...
Items per page:
1 - 3 of 3
BioCentury | Nov 10, 2017
Product R&D

Blueprint gets the GIST

...et al. “Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. ” Nature (2010) Michael Leviten, Senior Writer BLU-285 Blueprint Bio Oregon...
BioCentury | Jul 1, 2016
Company News

Management tracks

...and neuroscience area head of global clinical development at Shire plc (LSE:SHP; NASDAQ:SHPG). Biomarkers company Blueprint Bio Inc....
BioCentury | Jun 27, 2016
Financial News

Blueprint Bio completes venture financing

Blueprint Bio Inc. , Newport Beach, Calif. Business: Diagnostic Date completed: 2016-06-23 Type: Venture financing Raised: $7.5 million Investor: Forentis Fund WIR Staff Diagnostic...
Items per page:
1 - 3 of 3